Abstract
The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowing advanced practitioners to provide multiple myeloma patients an exclusively oral triplet therapy.
